XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)

XTX Topco Ltd acquired a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 22,438 shares of the company’s stock, valued at approximately $112,000.

Other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics in the second quarter worth approximately $70,000. SG Americas Securities LLC acquired a new position in shares of TScan Therapeutics in the 3rd quarter worth $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of TScan Therapeutics during the second quarter worth $90,000. MetLife Investment Management LLC lifted its holdings in shares of TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $134,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

Insider Activity

In other news, Director Barbara Klencke acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the acquisition, the director now owns 45,000 shares in the company, valued at approximately $238,050. The trade was a 12.50 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.76% of the stock is currently owned by corporate insiders.

TScan Therapeutics Trading Up 1.4 %

Shares of NASDAQ TCRX opened at $2.97 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics, Inc. has a one year low of $2.60 and a one year high of $9.69. The business has a 50-day moving average price of $4.57 and a two-hundred day moving average price of $5.68. The firm has a market capitalization of $158.51 million, a PE ratio of -2.80 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TCRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Wedbush restated an “outperform” rating and issued a $7.00 price target (down previously from $10.00) on shares of TScan Therapeutics in a research report on Tuesday, December 10th.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.